

BioMed Research International

Comparison of primer-probe sets among different master mixes for laboratory screening of Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2)

Short title: Comparison of primer-probe sets for laboratory screening of SARS-CoV-2

Hoang Quoc Cuong¹, Nguyen Duc Hai², Hoang Thuy Linh³, Nguyen Hoang Anh⁴, Nguyen Trung Hieu⁴, Cao Minh Thang⁴, Nguyen Thi Thanh Thao⁴, Phan Trong Lan¹

¹ Directorial board, Pasteur Institute Ho Chi Minh City, Vietnam

² Planning Division, Pasteur Institute in Ho Chi Minh City, Vietnam

³ Medical Analysis Department, Pasteur Institute in Ho Chi Minh City, Vietnam

⁴ Microbiology and Immunology Department, Pasteur Institute in Ho Chi Minh City, Vietnam

Correspondence:

HOANG QUOC CUONG, MD, Ph.D., Pasteur Institute in Ho Chi Minh City, Vietnam

167 Pasteur Street, District 3, Ho Chi Minh City, Vietnam (email: cuonghqpasteur@gmail.com)

Abstract: 173 words

Main text: 1883 words

Title: 132 characters; short title: 62 characters

Abstract

Background: The shortage of chemical reagents for severe acute respiratory syndrome - coronavirus 2 (*SARS-CoV-2*) diagnosis and the surge of *SARS-CoV-2* cases, especially in limited resource settings. Therefore, the combination of an optimal assay kit is necessary.

Methods: We compared the ability to screen *SARS-CoV-2* among three primer-probe sets added into two different master mixes (Invitrogen™ SuperScript™ III One-Step RT-PCR, and LightCycler Multiplex RNA Virus Master).

Results: The assay with TIB-Molbiol, IDT, and Phu Sa sets for LightCycler Multiplex RNA Virus Master or Invitrogen™ SuperScript™ III One-Step RT-PCR showed positive results from a single reaction of triplicate in the three days of 4.8 copies per reaction, with R-square and amplification efficiency (AE) were 0.97 and ranged from 107 to 108%, respectively.

Conclusions: Our findings indicated TIB-Molbiol, IDT, and Phu Sa primer-probe sets could be beneficial for the laboratory screening of *SARS-CoV-2* by Realtime RT-PCR assay of E gene. There is a need for considering the combination of these reagent sets as a new strategy to increase testing capacity for screening programs for COVID-19.

Keywords: primer-probe, comparison, COVID-19, *SARS-CoV-2*

1. Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (*SARS-CoV-2*) has a threat to human health which involves over 7,273,958 confirmed cases and 413,372 deaths [1]. While waiting for the coronavirus vaccine approval, molecular testing for *SARS-CoV-2* is one of the important strategies to prevent and reduce the rate of infection by case identification, isolation, social distancing, and proper treatment [2, 3].

Although many factors are leading to the low sensitivity of *SARS-CoV-2* such as: *a*) detection depends on the location of clinical specimens, *b*) low patient viral load, *c*) sporadic shedding, and *d*) discrepancy in detection kits from various producers [4, 5]. However, the molecular diagnosis of *SARS-CoV-2* using qRT-PCR assay is a gold standard method [6-8]. Consequently, the combination of an optimal assay kit is necessary because the shortage of chemical reagents for *SARS-CoV-2* diagnosis and the surge of *SARS-CoV-2* cases, especially in limited-resource settings.

In the present study, we aim to analyze the commonly used primer-probe sets, targeting E gene of *SARS-CoV-2* by the Realtime RT-PCR assay for laboratory screening to increase testing capacity in the context of thousands of overseas travelers returning to their countries.

2. MATERIALS AND METHODS

2.1. Primer-probe information

In this study, these three primer-probe sets based on the sequence information received from three different companies, TIB-Molbiol (Berlin, Germany), IDT (Integrated DNA Technologies, Skokie, Illinois, USA) and Phu Sa (Phu Sa Biochem, Vietnam) were used for comparative analysis [8] (*Supplementary Table 1*).

2.2. Viral preparation

The infection assays were performed in a biosafety level 3 laboratory. Vero E6 cells were infected with a clinical isolate *SARS-CoV-2*. After 72 hours, the virus medium was collected and heated at 65°C for 1 hour. Viral RNA was then isolated from the culture medium using the QIAamp viral RNA extraction Kit (Qiagen, Hilden, German) following the manufacturer's

instructions. The copy number of RNA extracted from *SARS-CoV-2* strain was estimated through a standard curve, which was published in a previous study [9].

2.3. Real-time reverse transcription polymerase chain reaction (RT-PCR) assay confirmation for *SARS-CoV-2*

RNA extracted specimens from the inactivated virus were tested for comparative assay of *SARS-CoV-2* by Real-time RT-PCR on a LightCycle 480 or ABI 7500 system following the manufacturer's protocol (Invitrogen™ SuperScript™ III One-Step RT-PCR System or LightCycler Multiplex RNA Virus Master). In this study, the reaction combination was made up by multiplying the volumes of each reagent in Table 1.

Table 1. Volumes of reagents for reactions using two different polymerase enzymes combined with three primer-probe sets.

No.	Reagent	LightCycler Multiplex RNA Virus Master (TIB-Molbiol)	LightCycler Multiplex RNA Virus Master (IDT/Phu Sa)	Invitrogen™ SuperScript™ III One-Step RT-PCR System (TIB-Molbiol)	Invitrogen™ SuperScript™ III One-Step RT-PCR System (IDT/Phu Sa)
1	H ₂ O (RNAse free)	10.4 µL	8.4 µL	5.6 µL	3.6 µL
2	Reaction mix	4.0 µL	4.0 µL	12.5 µL	12.5 µL
3	Primer E_Sarbeco_F1		1.0 µL		1.0 µL
4	Primer E_Sarbeco_R2	0.5 µL	1.0 µL	0.5 µL	1.0 µL
5	Primer E_Sarbeco_R2		0.5 µL		0.5 µL
6	MgSO ₄ (50nM)	0.4 µL	-	0.4 µL	0.4 µL
7	RT enzyme	0.1 µL	0.1 µL	1.0 µL	1.0 µL
8	Template RNA	5.0 µL	5.0 µL	5.0 µL	5.0 µL
	Total	20 µL	20 µL	25 µL	25 µL

Real-time RT-PCR conditions applied in the present study with details described in Table 2. A cycle threshold value (Ct-value) of ≥ 40 was defined as a negative test [8].

Table 2. RT-PCR conditions applied in the present study.

Parameter	RT step	Denaturation	Cycling	
Cycles	1	1	45	
Target temperature (°C)	55	94	94	58
Duration (hours/minutes/seconds)	00:10:00	00:03:00	00:00:15	00:00:30

2.4. Analysis

In this study, Data were entered using Epi-Data version 3.1 (EpiData Association, Odense, Denmark, 2005), and all statistical analysis were performed using Stata version 13.0 (StataCorp, TX, 2013).

The results were summarized using means and standard deviation (SD) for continuous variables. Linear regression analysis was performed to estimate the R-square. Amplification efficiency (AE) was calculated using the equation $AE = -1 + 10^{(-1/\text{slope})}$ [10].

2.5. Ethical statement

Study protocol has been reviewed and ratified by the Pasteur Institute Ho Chi Minh City Institutional Review Board (reference number: 433/XN-PAS).

3. RESULTS

In this study, the assay with TIB-Molbiol, IDT, and Phu Sa sets for LightCycler Multiplex RNA Virus Master showed positive results from a single reaction of triplicate in the three days of 4.8 copies/reaction (Table 3).

Table 3. The results of LightCycler Multiplex RNA Virus Master with three primer-probe sets (IDT, Phu Sa, TIB-Molbiol).

Dilution	Viral copies	TIB-Molbiol Ct-Values			IDT Ct-values			Phu Sa Ct-Values		
		Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	Day 1	Day 2	Day 3
1:10 ⁷	96	34.47	34.22	35.11	34.82	34.22	35.18	34.51	34.91	34.93
		33.87	34.38	35.3	35.28	34.66	34.53	34.62	34.67	34.63
		34.5	34.75	35.14	35.25	34.49	34.85	35.12	34.74	34.85
1:10 ⁷ ½	48	36.03	36.64	36.25	36.16	36.68	35.72	36.13	36.43	36.12
		36.81	35.35	35.87	36.32	35.97	36.35	36.62	36.17	36.35
		35.72	35.87	36.61	36.78	36.13	36.76	36.45	36.24	36.01
1:10 ⁸	9.6	38.3	38.11	37.47	37.49	37.85	38.25	37.92	37.51	37.75
		36.87	38.14	37.38	37.82	38.28	37.22	37.63	37.93	38.22
		37.22	37.5	37.75	37.66	37.53	38.18	37.84	37.67	37.62
1:10 ⁸ ½	4.8	39.25	38.37	39.03	39.35	39.58	39.24	39.12	39.24	39.21
		38.88	38.72	38.97	39.16	39.03	38.62	39.13	39.15	39.32
		39.24	39.5	39.21	39.25	38.99	39.28	39.17	39.33	39.41

Dilution	Viral copies	TIB-Molbiol Ct-Values			IDT Ct-values			Phu Sa Ct-Values		
		Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	Day 1	Day 2	Day 3
Negative control		-	-	-	-	-	-	-	-	-
Positive control		22.33	25.31	25.60	30.0	25.4	28.18	26.37	29.48	26.37

“-”: Undetected

The Ct-values (mean±SD) of E gene (TIB-Mobiol), IDT, and Phu Sa at 1:10⁸½ were 39.02±0.34, 39.17±0.34 and 39.23±0.10, respectively. R² value from TIB-Mobiol, IDT, and Phu Sa showed equal values of 0.97. Similarly, the AE of each set was also showing the same value, for the figures of TIB-Mobiol and IDT were 107; and Phu Sa was 108 (Table 4).

Table 4. Comparison of Ct-value means for LightCycler Multiplex RNA Virus Master with three primer-probe sets (IDT, Phu Sa, TIB-Molbiol).

Dilution	Viral copies	TIB-Molbiol Ct-Values				IDT Ct-values				Phu Sa Ct-Values			
		Mean	SD	R ²	AE	Mean	SD	R ²	AE	Mean	SD	R ²	AE
1:10 ⁷	96	34.64	0.47			34.81	0.37			34.78	0.19		
1:10 ⁷ ½	48	36.13	0.49	0.97	107	36.32	0.36	0.97	107	36.28	0.20	0.97	108
1:10 ⁸	9.6	37.64	0.47			37.81	0.37			37.79	0.22		
1:10 ⁸ ½	4.8	39.02	0.34			39.17	0.27			39.23	0.10		

The assay with TIB-Molbiol, IDT and Phu Sa primer-probe sets for the Invitrogen™ SuperScript™ III One-Step RT-PCR System exhibited positive results from a single reaction of triplicate in the three days of 4.8 copies/reaction (Table 5). Besides the results for LightCycler Multiplex RNA Virus Master, TIB-Molbiol, IDT and Phu Sa sets, they showed the same sensitivity in low concentrations.

Table 5. The results of Invitrogen™ SuperScript™ III One-Step RT-PCR System with three primer-probe (IDT, Phu Sa, TIB-Molbiol).

Dilution	Copies/ reaction	TIB-Molbiol Ct-Values			IDT Ct-values			Phu Sa Ct-Values		
		Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	Day 1	Day 2	Day 3
1:10 ⁸	96	34.23	34.51	34.81	35.07	34.91	35.03	34.34	35.21	35.31
		34.16	34.66	34.6	35.15	33.94	34.34	35.03	34.87	34.62
		34.09	34.09	34.83	35.12	34.82	34.21	34.24	34.86	35.32
1:10 ⁸ ½	48	36.31	35.72	36.16	36.53	35.44	35.84	35.84	36.36	36.12
		35.58	35.58	36.34	36.64	36.41	36.34	36.81	36.53	35.74
		35.69	36	36.14	36.58	35.71	36.66	36.71	36.34	36.83
1:10 ⁹	9.6	37.09	37.83	37.16	36.94	37.34	37.91	37.34	38.32	38.31
		37.23	37.09	37.71	38.03	38.07	38.15	37.86	38.21	37.87
		37.51	37.66	37.6	38.1	37.82	37.19	38.03	37.62	37.24
1:10 ⁹ ½	4.8	38.59	38.59	38.66	39.62	39.32	38.82	38.82	39.72	38.74
		39.33	38.63	39.1	38.42	38.71	39.51	39.77	39.59	39.52
		39.16	39.01	39.31	39.46	39.41	39.55	39.36	39.12	39.37
Negative control		-	-	-	-	-	-	-	-	-
Positive control		24.27	25.91	22.81	28.40	28.38	26.72	20.81	30.56	29.39

“-”: Undetected

In this study, we found that the R-square values from TIB-Molbiol, IDT and Phu Sa were the same (0.97). Similar to the results of LightCycler Multiplex RNA Virus Master, the AE of IDT, and Phu Sa was also the same value (108); and 107 for TIB-Molbiol (Table 6).

Table 6. Comparison of Ct-value means for Invitrogen™ SuperScript™ III One-Step RT-PCR System with three primer-probe sets (IDT, Phu Sa, TIB-Molbiol).

Dilution	Viral copies	TIB-Molbiol Ct-Values				IDT Ct-values				Phu Sa Ct-Values			
		Mean	SD	R ²	AE	Mean	SD	R ²	AE	Mean	SD	R ²	AE
1:10 ⁷	96	34.44	0.30	0.97	107	34.73	0.45	0.97	108	34.87	0.39	0.97	108
1:10 ⁷ ½	48	35.95	0.31			36.24	0.44			36.36	0.40		
1:10 ⁸	9.6	37.43	0.29			37.73	0.45			37.87	0.40		
1:10 ⁸ ½	4.8	38.93	0.30			39.20	0.43			39.33	0.37		

4. DISCUSSION

In this study, we reported the comparative analysis of laboratory screening for *SARS-CoV-2* among three primer-probe sets added into two different master mixes (Invitrogen™ SuperScript™ III One-Step RT-PCR, and LightCycler Multiplex RNA Virus Master). The initial analysis showed the combination of TIB-Molbiol, IDT, and Phu Sa primer-probe sets were quite sensitive to positive results (4.8 copies/reaction) among Invitrogen™ SuperScript™ III One-Step RT-PCR System (Table 7). In terms of LightCycler Multiplex RNA Virus Master, TIB-Molbiol, IDT, and Phu Sa primer-probe sets also showed the same sensitivity (4.8 copies/reaction). The R-square of each primer-probe set among the different master mixes were around 0.97, which was in agreement with a previous study [11]. Also, the values of AE in each primer-probe set among different master mixes reach the accepted criteria of AE ranged from 90-110% [10].

Our findings found that these primer-probe sets added into two different master mixes were sensitive and reliable for laboratory screening of *SARS-CoV-2*. Hence, these primer-probe sets could be beneficial for the laboratory screening of *SARS-CoV-2* by Real-time RT-PCR assay of E gene. Several previous studies have also shown that the selection of the best primer-probe sets and equipment for *SARS-CoV-2* screening and diagnosis were an urgent and important solution for prevention and control COVID-19 [11, 12].

Table 7. Summary of the criteria for three primer-probe sets.

Dilution	Viral copies	TIB-Molbiol				IDT				Phu Sa			
		Ct-Values				Ct-values				Ct-Values			
		LightCycler		Invitrogen™		LightCycler		Invitrogen™		LightCycler		Invitrogen™	
		R ²	AE	R ²	AE	R ²	AE	R ²	AE	R ²	AE	R ²	AE
1:10 ⁸	96												
1:10 ⁸ ½	48	0.97	107	0.97	107	0.97	107	0.97	108	0.97	108	0.97	108
1:10 ⁹	9.6												
1:10 ⁹ ½	4.8												

Our findings are partly helpful to improve the capacity of suspected case screenings and to reduce the affected performance of the testing that yield false-negative results [13]. Furthermore,

our findings could also contribute to gain better understandings of the combination of the best reagents for *SARS-CoV-2* screening to select the most optimum reagents to effectively halt COVID-19.

In the context of the COVID-19 tends to be endemic, the social distancing measure is no longer the ideal solution and while waiting for coronavirus vaccine approval, air travel should return to normal, especially thousands of overseas travelers from the epidemic areas could return to their countries. Therefore, the combination of the reagent sets is essential for screening these subjects. The results of this study are a prelude for other studies to improve the testing capacity of screening suspected cases.

5. CONCLUSION

Our findings indicate TIB-Molbiol, IDT, and Phu Sa primer-probe sets could be beneficial for the laboratory screening of *SARS-CoV-2* by Realtime RT-PCR assay of E gene. There is a need for considering the combination of these reagent sets as a new strategy to increase the testing capacity for screening programs for COVID-19.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflict interest

The authors have no conflicts of interest.

Acknowledgments

We would like to thank colleagues at Pasteur Institute, Ho Chi Minh City for supporting the study. Thanks for Mr. Alan Tan, Sydney, Australia edited and proofread the manuscript.

Declaration of Funding

This research received no external funding.

Abbreviation

RT-PCR: Reverse transcription polymerase chain reaction

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

COVID-19: Corona virus infected diseases 19

Supplementary table. Information of primers and probes were used in this study.

No.	Primer/Probe	Country	Type	Sequence (5' to 3')	Position	Target
1	IDT	US	F1	ACAGGTACGTTAATAGTTAATAGCGT	26,141-	E
2	Phu Sa	Vietnam	R2	ATATTGCAGCAGTACGCACACA	26,253	
3	Tib-Molbiol	Germany	P1	FAM- ACACTAGCCATCCTTACTGCGCTTCGBBQ		

References

1. Organizatin, W.H., *Coronavirus disease 2019 (COVID-19) Situation Report – 143*. 2020.
2. Hellewell, J., et al., *Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts*. The Lancet Global Health, 2020.
3. Zheng, C., et al., *Risk-adapted Treatment Strategy For COVID-19 Patients*. International Journal of Infectious Diseases, 2020.
4. Toms, D., J. Li, and H.Y. Cai, *Evaluation of WHO listed COVID-19 qPCR primers and probe in silico with 375 SERS-CoV-2 full genome sequences*. medRxiv, 2020.
5. Nalla, A.K., et al., *Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit*. Journal of Clinical Microbiology, 2020.
6. Drosten, C., et al., *Identification of a novel coronavirus in patients with severe acute respiratory syndrome*. New England journal of medicine, 2003. **348**(20): p. 1967-1976.
7. Poon, L.L., et al., *A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors*. Journal of clinical virology, 2004. **30**(3): p. 214-217.
8. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR*. Eurosurveillance, 2020. **25**(3).
9. Lan, P.T., et al., *Development of standardized specimens with known concentrations for severe acute respiratory syndrome coronavirus 2 Realtime-RT-PCR testing validation*. Bull World Health Organ. E-pub: 20 April 2020, 2020.
10. Ruijter, J., et al., *Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data*. Nucleic acids research, 2009. **37**(6): p. e45-e45.
11. Jung, Y.J., et al., *Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2*. BioRxiv, 2020.
12. Casto, A.M., et al., *Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit*. medRxiv, 2020.
13. Stadhouders, R., et al., *The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay*. The Journal of Molecular Diagnostics, 2010. **12**(1): p. 109-117.